Canaccord Genuity Reiterates a 'Buy' on Momenta (MNTA); Lovenox Authorized Generic Launched
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $15.00.
Canaccord Genuity analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone potential, biosimilars. We think m-enox sales revenue to Momenta will decline Q4/11 on launches of authorized generic and likely Amphastar/WPI enox. We still think the upcoming Teva (Nasdaq: TEVA) generic Copaxone infringement lawsuit will be decided in Momenta/Sandoz’s favor mid-2012 and Momenta will become a biosimilars development leader."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $13.96 yesterday.
Canaccord Genuity analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone potential, biosimilars. We think m-enox sales revenue to Momenta will decline Q4/11 on launches of authorized generic and likely Amphastar/WPI enox. We still think the upcoming Teva (Nasdaq: TEVA) generic Copaxone infringement lawsuit will be decided in Momenta/Sandoz’s favor mid-2012 and Momenta will become a biosimilars development leader."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $13.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Alfen (ALFEN:NA) (ALFNF) to Hold
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
